This is a repository copy of THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS - CURRENT UPDATE.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/111272/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1136/jnnp-2016-315106.153

This publication is protected by copyright. All rights reserved. This is an author produced version of an abstract published in the Journal of Neurology, Neurosurgery and Psychiatry. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
THE MS-SMART TRIAL IN SECONDARY PROGRESSIVE MS—CURRENT UPDATE

Jeremy Chataway,1 Siddharthan Chandran,1 David Miller,2 Peter Connick,2 Gavin Giovannoni,3 Sue Pavitt,4 Nigel Stallard,5 Glive Hawkins,6 Basil Sharrack,7 Domenico Plantone1,2,3,4,5,6,7,8. 1 University College London; 2 University of Edinburgh; 3 Queen Mary University of London; 4 University of Leeds; 5 University of Warwick; 6 University Hospital of North Staffordshire; 7 University of Sheffield; 8 on behalf of the MS-SMART trialists

10.1136/jnnp-2016-315106.153

MS-SMART is an ongoing multicentre, multi-arm, double blind, placebo-controlled phase IIb randomised controlled trial to establish whether putative neuroprotective drugs (fluoxetine, riluzole, amiloride or placebo) can slow down the progression of brain volume loss in secondary progressive multiple sclerosis (SPMS) over 96 weeks using MRI-derived Percentage Brain Volume Change (PBVQ) as the primary outcome. 360 patients have been screened so far, 328 (92%) consented and 272 randomized (65% of the total UK cohort—440). Patients will have outcome-data collected after 0, 24, 48 and 96 weeks. The trial is using a range of conventional and novel imaging techniques to better understand neuroprotection in SPMS. Core data includes: new and enlarging T2 lesions count, persistent new T1 hypointense lesion, whole brain atrophy, grey matter volume, and advanced imaging in 2 centres [cervical cord area change, MR spectroscopy and Magnetic Transfer Ratio (MTR)]. Additional measures include: CSF neurofilament levels and optical coherence tomography (OCT) to measure Retinal Nerve Fibre Layer (RNFL) thickness. This abstract describes the ongoing status of the trial. This independent research is awarded by the Efficacy and Mechanism Evaluation Programme (EME) and funded by the Medical Research Council (MRC) and the Multiple Sclerosis Society (MS Society) and managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership.